Drug Trial Radar · NCT07640347
Comparative Effects of Doxercalciferol and Calcitriol on Secondary Hyperparathyroidism in ESRD
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
Jul 5, 2026
Primary completion
May 30, 2027
Study completion May 30, 2027
Sponsor
- Lead sponsor
- Chittagong Medical CollegeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Secondary hyperparathyroidism (SHPT) is a common complication of advanced chronic kidney disease (CKD), caused by phosphate retention and vitamin D deficiency, leading to elevated parathyroid hormone (PTH) levels and increased bone and cardiovascular complications. Active vitamin D analogs such as calcitriol and doxercalciferol are used to suppress PTH levels, though they differ in pharmacologic properties and effects on mineral metabolism. Intravenous preparations may offer improved bioavailability and adherence in hemodialysis patients.This randomized controlled trial will be conducted in the Department of Nephrology at Chittagong Medical College Hospital among 98 adult hemodialysis patients with SHPT. Participants will be randomly assigned to receive either intravenous doxercalciferol or oral calcitriol. The study aims to compare their effectiveness in lowering PTH levels and evaluate safety outcomes. Continuous variables will be expressed as mean ± standard deviation, while categorical variables will be presented as frequencies and percentages. Independent t-tests, chi-square tests, or Fisher's exact tests will be used for statistical comparisons. Data analysis will be performed using SPSS version 27.0, with a p-value \<0.05 considered statistically significant.
Conditions
- Lowering Parathyroid Hormone Level in Patients on Hemodioalysis
Interventions
Doxercalciferol administrationDrug
receive iv doxercalciferol 4 microgram after dialysis for 12 weeks in addition to their standard routine medications.
oral calcitriol 0.25 microgramDrug
Control group will receive oral calcitriol 0.25 microgram once daily in addition to their standard routine medications for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in serum Parathyroid Hormone (PTH) levelsTime frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.